S&P 500   3,811.15 (-0.48%)
DOW   30,932.37 (-1.50%)
QQQ   314.14 (+0.42%)
AAPL   121.26 (+0.22%)
MSFT   232.38 (+1.48%)
FB   257.62 (+1.15%)
GOOGL   2,021.91 (+0.30%)
AMZN   3,092.93 (+1.17%)
TSLA   675.50 (-0.99%)
NVDA   548.58 (+3.06%)
BABA   237.76 (-1.01%)
CGC   32.75 (-1.39%)
GE   12.54 (-1.72%)
MU   91.53 (+3.87%)
NIO   45.78 (-2.20%)
AMD   84.51 (+2.54%)
T   27.89 (-2.58%)
F   11.70 (-0.51%)
ACB   10.52 (-2.77%)
DIS   189.04 (-1.02%)
BA   212.01 (-2.05%)
NFLX   538.85 (-1.44%)
BAC   34.71 (-3.40%)
S&P 500   3,811.15 (-0.48%)
DOW   30,932.37 (-1.50%)
QQQ   314.14 (+0.42%)
AAPL   121.26 (+0.22%)
MSFT   232.38 (+1.48%)
FB   257.62 (+1.15%)
GOOGL   2,021.91 (+0.30%)
AMZN   3,092.93 (+1.17%)
TSLA   675.50 (-0.99%)
NVDA   548.58 (+3.06%)
BABA   237.76 (-1.01%)
CGC   32.75 (-1.39%)
GE   12.54 (-1.72%)
MU   91.53 (+3.87%)
NIO   45.78 (-2.20%)
AMD   84.51 (+2.54%)
T   27.89 (-2.58%)
F   11.70 (-0.51%)
ACB   10.52 (-2.77%)
DIS   189.04 (-1.02%)
BA   212.01 (-2.05%)
NFLX   538.85 (-1.44%)
BAC   34.71 (-3.40%)
S&P 500   3,811.15 (-0.48%)
DOW   30,932.37 (-1.50%)
QQQ   314.14 (+0.42%)
AAPL   121.26 (+0.22%)
MSFT   232.38 (+1.48%)
FB   257.62 (+1.15%)
GOOGL   2,021.91 (+0.30%)
AMZN   3,092.93 (+1.17%)
TSLA   675.50 (-0.99%)
NVDA   548.58 (+3.06%)
BABA   237.76 (-1.01%)
CGC   32.75 (-1.39%)
GE   12.54 (-1.72%)
MU   91.53 (+3.87%)
NIO   45.78 (-2.20%)
AMD   84.51 (+2.54%)
T   27.89 (-2.58%)
F   11.70 (-0.51%)
ACB   10.52 (-2.77%)
DIS   189.04 (-1.02%)
BA   212.01 (-2.05%)
NFLX   538.85 (-1.44%)
BAC   34.71 (-3.40%)
S&P 500   3,811.15 (-0.48%)
DOW   30,932.37 (-1.50%)
QQQ   314.14 (+0.42%)
AAPL   121.26 (+0.22%)
MSFT   232.38 (+1.48%)
FB   257.62 (+1.15%)
GOOGL   2,021.91 (+0.30%)
AMZN   3,092.93 (+1.17%)
TSLA   675.50 (-0.99%)
NVDA   548.58 (+3.06%)
BABA   237.76 (-1.01%)
CGC   32.75 (-1.39%)
GE   12.54 (-1.72%)
MU   91.53 (+3.87%)
NIO   45.78 (-2.20%)
AMD   84.51 (+2.54%)
T   27.89 (-2.58%)
F   11.70 (-0.51%)
ACB   10.52 (-2.77%)
DIS   189.04 (-1.02%)
BA   212.01 (-2.05%)
NFLX   538.85 (-1.44%)
BAC   34.71 (-3.40%)
Log in
NASDAQ:INCY

Incyte News Headlines

$78.66
+0.21 (+0.27 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$77.77
Now: $78.66
$79.64
50-Day Range
$78.45
MA: $89.50
$100.50
52-Week Range
$62.48
Now: $78.66
$110.36
Volume1.69 million shs
Average Volume1.34 million shs
Market Capitalization$17.29 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.96

Headlines

Incyte (NASDAQ INCY) News Headlines Today

Source:
SourceHeadline
Incyte (NASDAQ:INCY) Lifted to "B-" at TheStreetIncyte (NASDAQ:INCY) Lifted to "B-" at TheStreet
marketbeat.com - February 11 at 8:24 AM
Incyte Corp. stock rises Friday, outperforms market - MarketWatchIncyte Corp. stock rises Friday, outperforms market - MarketWatch
marketwatch.com - February 26 at 7:01 PM
Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Retifanlimab as a Treatment for Patients with Squamous Cell Anal Carcinoma (SCAC) - Business WireIncyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Retifanlimab as a Treatment for Patients with Squamous Cell Anal Carcinoma (SCAC) - Business Wire
businesswire.com - February 26 at 1:22 PM
Incytes retifanlimab application validated in Europe - Seeking AlphaIncyte's retifanlimab application validated in Europe - Seeking Alpha
seekingalpha.com - February 26 at 8:21 AM
Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Retifanlimab as a Treatment for Patients with Squamous Cell Anal Carcinoma (SCAC) - Yahoo FinanceIncyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Retifanlimab as a Treatment for Patients with Squamous Cell Anal Carcinoma (SCAC) - Yahoo Finance
finance.yahoo.com - February 26 at 3:21 AM
Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Retifanlimab as a Treatment for Patients with Squamous Cell Anal Carcinoma (SCAC)Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Retifanlimab as a Treatment for Patients with Squamous Cell Anal Carcinoma (SCAC)
finance.yahoo.com - February 26 at 3:21 AM
Incyte Announces Acceptance and Priority Review of sNDA for Jakafi® (ruxolitinib) as a Treatment for Patients with Chronic Graft-Versus-Host Disease - Business WireIncyte Announces Acceptance and Priority Review of sNDA for Jakafi® (ruxolitinib) as a Treatment for Patients with Chronic Graft-Versus-Host Disease - Business Wire
businesswire.com - February 22 at 10:57 PM
Incyte (INCY) Announces Acceptance and Priority Review of sNDA for Jakafi as Treatment for Patients with Chronic Graft-Versus-Host Disease - StreetInsider.comIncyte (INCY) Announces Acceptance and Priority Review of sNDA for Jakafi as Treatment for Patients with Chronic Graft-Versus-Host Disease - StreetInsider.com
streetinsider.com - February 22 at 5:56 PM
Incyte Corp. stock outperforms market despite losses on the day - MarketWatchIncyte Corp. stock outperforms market despite losses on the day - MarketWatch
marketwatch.com - February 22 at 5:56 PM
Incyte Announces Acceptance and Priority Review of sNDA for Jakafi® (ruxolitinib) as a Treatment for Patients with Chronic Graft-Versus-Host Disease - Yahoo FinanceIncyte Announces Acceptance and Priority Review of sNDA for Jakafi® (ruxolitinib) as a Treatment for Patients with Chronic Graft-Versus-Host Disease - Yahoo Finance
finance.yahoo.com - February 22 at 5:56 PM
Incyte Says FDA Grants Priority Review For Eczema Cream; Street Sees 20% Upside - Yahoo FinanceIncyte Says FDA Grants Priority Review For Eczema Cream; Street Sees 20% Upside - Yahoo Finance
finance.yahoo.com - February 22 at 12:56 PM
Incyte Announces Acceptance and Priority Review of sNDA for Jakafi® (ruxolitinib) as a Treatment for Patients with Chronic Graft-Versus-Host DiseaseIncyte Announces Acceptance and Priority Review of sNDA for Jakafi® (ruxolitinib) as a Treatment for Patients with Chronic Graft-Versus-Host Disease
finance.yahoo.com - February 22 at 12:56 PM
Incyte Says FDA Grants Priority Review For Eczema Cream; Street Sees 20% UpsideIncyte Says FDA Grants Priority Review For Eczema Cream; Street Sees 20% Upside
finance.yahoo.com - February 22 at 12:56 PM
FDA accepts Incytes ruxolitinib NDA with Priority Review - Seeking AlphaFDA accepts Incyte's ruxolitinib NDA with Priority Review - Seeking Alpha
seekingalpha.com - February 19 at 7:39 PM
FDA Accepts Incytes Ruxolitinib Cream US Application For Chronic Skin Disease - BenzingaFDA Accepts Incyte's Ruxolitinib Cream US Application For Chronic Skin Disease - Benzinga
benzinga.com - February 19 at 7:39 PM
Incyte Announces Acceptance and Priority Review of NDA for Ruxolitinib Cream for Atopic Dermatitis - Business WireIncyte Announces Acceptance and Priority Review of NDA for Ruxolitinib Cream for Atopic Dermatitis - Business Wire
businesswire.com - February 19 at 7:39 PM
Incyte Announces Acceptance and Priority Review of NDA for Ruxolitinib Cream for Atopic Dermatitis - Yahoo FinanceIncyte Announces Acceptance and Priority Review of NDA for Ruxolitinib Cream for Atopic Dermatitis - Yahoo Finance
finance.yahoo.com - February 19 at 2:37 PM
Incyte Announces Acceptance and Priority Review of NDA for Ruxolitinib Cream for Atopic DermatitisIncyte Announces Acceptance and Priority Review of NDA for Ruxolitinib Cream for Atopic Dermatitis
finance.yahoo.com - February 19 at 9:36 AM
Incyte Q4 2020 Shows Strength; Stock At An Attractive Price - Seeking AlphaIncyte Q4 2020 Shows Strength; Stock At An Attractive Price - Seeking Alpha
seekingalpha.com - February 18 at 8:23 AM
Incyte Corp. stock rises Wednesday, outperforms market - MarketWatchIncyte Corp. stock rises Wednesday, outperforms market - MarketWatch
marketwatch.com - February 17 at 5:56 PM
Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatchIncyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
marketwatch.com - February 16 at 4:42 PM
Incyte: Another Buy Opportunity - Seeking AlphaIncyte: Another Buy Opportunity - Seeking Alpha
seekingalpha.com - February 16 at 11:42 AM
Incyte: Another Buy OpportunityIncyte: Another Buy Opportunity
seekingalpha.com - February 16 at 9:39 AM
$653.50 Million in Sales Expected for Incyte Co. (NASDAQ:INCY) This Quarter$653.50 Million in Sales Expected for Incyte Co. (NASDAQ:INCY) This Quarter
americanbankingnews.com - February 14 at 2:20 AM
Incyte Corp. stock underperforms Friday when compared to competitors - MarketWatchIncyte Corp. stock underperforms Friday when compared to competitors - MarketWatch
marketwatch.com - February 13 at 12:15 AM
 Brokerages Expect Incyte Co. (NASDAQ:INCY) to Post $0.68 Earnings Per Share Brokerages Expect Incyte Co. (NASDAQ:INCY) to Post $0.68 Earnings Per Share
americanbankingnews.com - February 12 at 4:20 PM
Incyte Corp. stock falls Thursday, underperforms market - MarketWatchIncyte Corp. stock falls Thursday, underperforms market - MarketWatch
marketwatch.com - February 11 at 7:01 PM
Edited Transcript of INCY.OQ earnings conference call or presentation 9-Feb-21 1:00pm GMT - Yahoo FinanceEdited Transcript of INCY.OQ earnings conference call or presentation 9-Feb-21 1:00pm GMT - Yahoo Finance
finance.yahoo.com - February 11 at 2:01 PM
Recap: Incyte Q4 Earnings - Yahoo FinanceRecap: Incyte Q4 Earnings - Yahoo Finance
finance.yahoo.com - February 11 at 2:01 PM
Incyte Corp. stock underperforms Wednesday when compared to competitors - MarketWatchIncyte Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
marketwatch.com - February 10 at 7:08 PM
Incyte is weighed down by SVB downgrade following Q4 earnings release - Seeking AlphaIncyte is weighed down by SVB downgrade following Q4 earnings release - Seeking Alpha
seekingalpha.com - February 10 at 2:05 PM
Morgan Stanley Cuts Incyte (NASDAQ:INCY) Price Target to $93.00Morgan Stanley Cuts Incyte (NASDAQ:INCY) Price Target to $93.00
americanbankingnews.com - February 10 at 9:42 AM
Incyte Q4 topline up 36%, posts 2021 forecast - Seeking AlphaIncyte Q4 topline up 36%, posts 2021 forecast - Seeking Alpha
seekingalpha.com - February 10 at 9:05 AM
Recap: Incyte Q4 Earnings - BenzingaRecap: Incyte Q4 Earnings - Benzinga
benzinga.com - February 10 at 9:05 AM
Incyte Corp (INCY) Q4 2020 Earnings Call Transcript - Motley FoolIncyte Corp (INCY) Q4 2020 Earnings Call Transcript - Motley Fool
fool.com - February 10 at 9:05 AM
Incyte Corporations (INCY) CEO Hervé Hoppenot on Q4 2020 Results - Earnings Call Transcript - Seeking AlphaIncyte Corporation's (INCY) CEO Hervé Hoppenot on Q4 2020 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - February 10 at 9:05 AM
Whats Behind Incytes Better-Than-Expected Q4 Earnings - Motley FoolWhat's Behind Incyte's Better-Than-Expected Q4 Earnings - Motley Fool
fool.com - February 10 at 9:05 AM
SVB Leerink Lowers Incyte (NASDAQ:INCY) to Market PerformSVB Leerink Lowers Incyte (NASDAQ:INCY) to Market Perform
americanbankingnews.com - February 10 at 7:48 AM
Incyte Corporation Q4 adjusted earnings Beat EstimatesIncyte Corporation Q4 adjusted earnings Beat Estimates
nasdaq.com - February 10 at 12:30 AM
Incyte Reports 2020 Fourth Quarter and Year-End Financial Results, Provides 2021 Financial Guidance and Updates on Key Clinical Programs - Business WireIncyte Reports 2020 Fourth Quarter and Year-End Financial Results, Provides 2021 Financial Guidance and Updates on Key Clinical Programs - Business Wire
businesswire.com - February 9 at 7:28 PM
Bristol Myers (BMY) Gets European Commission Nod for Inrebic - NasdaqBristol Myers (BMY) Gets European Commission Nod for Inrebic - Nasdaq
nasdaq.com - February 9 at 2:28 PM
Incyte (INCY) Q4 Earnings and Revenues Top Estimates - Yahoo FinanceIncyte (INCY) Q4 Earnings and Revenues Top Estimates - Yahoo Finance
finance.yahoo.com - February 9 at 2:28 PM
Recap: Incyte Q4 EarningsRecap: Incyte Q4 Earnings
finance.yahoo.com - February 9 at 2:28 PM
Incyte (INCY) Q4 Earnings and Revenues Top EstimatesIncyte (INCY) Q4 Earnings and Revenues Top Estimates
finance.yahoo.com - February 9 at 2:28 PM
Incyte Corp (INCY) Q4 2020 Earnings Call TranscriptIncyte Corp (INCY) Q4 2020 Earnings Call Transcript
finance.yahoo.com - February 9 at 2:28 PM
Whats Behind Incytes Better-Than-Expected Q4 EarningsWhat's Behind Incyte's Better-Than-Expected Q4 Earnings
finance.yahoo.com - February 9 at 2:28 PM
INCY: Is Incyte a Good Biotech Stock to Add to Your Portfolio? - StockNews.comINCY: Is Incyte a Good Biotech Stock to Add to Your Portfolio? - StockNews.com
stocknews.com - February 9 at 9:27 AM
Incyte Q4 20 Earnings Conference Call At 8:00 AM ET - NasdaqIncyte Q4 20 Earnings Conference Call At 8:00 AM ET - Nasdaq
nasdaq.com - February 9 at 9:27 AM
Incyte Reports 2020 Fourth Quarter and Year-End Financial Results, Provides 2021 Financial Guidance and Updates on Key Clinical ProgramsIncyte Reports 2020 Fourth Quarter and Year-End Financial Results, Provides 2021 Financial Guidance and Updates on Key Clinical Programs
finance.yahoo.com - February 9 at 9:27 AM
Incyte Q4 2020 Earnings Preview - Seeking AlphaIncyte Q4 2020 Earnings Preview - Seeking Alpha
seekingalpha.com - February 8 at 6:45 PM
Wednesday 2/3 Insider Buying Report: ARAY, TRIN - NasdaqWednesday 2/3 Insider Buying Report: ARAY, TRIN - Nasdaq
nasdaq.com - February 4 at 3:07 AM
This page was last updated on 2/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.